Ikonisys S A : Investors presentation

Management Presentation

February 2022

CONFIDENTIAL

Disclaimer

This document has been prepared by ikonisys Inc. (the "Company" and, with its subsidiary, the "Group") only for information purposes. It contains only summary information and, therefore, it is preliminary in nature. Furthermore it has been drafted without claiming to be exhaustive.

This presentation ("Presentation") is confidential and, as such, has not been prepared with a view to public disclosure and, except with the prior written consent of the Company, it cannot be used by the recipient for any purpose nor can it be disclosed, copied, recorded, transmitted, further distributed to any other person or published, in whole or in part, by any medium or in any form for any purpose. Therefore, the recipient undertakes vis-à-vis the Company (i) to keep secret any information of whatever nature relating to the Company and its affiliates including, without limitation, the fact that the information has been provided ("Information"), (ii) not to disclose any Information to anyone, (iii) not to make or allow any public announcements or communications concerning the Information and (iv) to use reasonable endeavours to ensure that Information are protected against unauthorized access.

This Presentation is not an advertisement and in no way constitutes a proposal to execute a contract, an offer or invitation to purchase, subscribe or sell for any securities and neither it nor any part of it shall form the basis of or be relied upon in connection with any contract or commitment or investments decision whatsoever. This Presentation, any presentation made in connection herewith and any accompanying materials are preliminary and subject to correction and amendment in their entirety and are made available solely for discussion and feedback purposes and do not, and are not intended to, constitute any sort of recommendation, invitation or solicitation regarding any investment in the shares of the Company. The information contained herein is only preliminary and indicative and does not purport to contain the information that would be required to evaluate the Company, its financial position and/or any investment decision. Accordingly, by attending any presentation in which this document is made available or by receiving this document through any other means, you represent that you are able to receive this document without contravention of any legal or regulatory restrictions applicable to you. This document is given in conjunction with an oral presentation and should not be taken out of context. Any decision to purchase, subscribe or sell for securities will have to be made independently of this Presentation. Therefore, nothing in this Presentation shall create any binding obligation or liability on the Company and its affiliates and any of their advisors or representatives.

No representation or warranty, express or implied, is or will be given by the Company or any of their respective subsidiary undertakings, affiliates, agents or advisers or any of such persons' affiliates, directors, officers or employees or any other person as to the accuracy, completeness, fairness or verification of any information or opinions contained in these materials and no responsibility or liability whatsoever is accepted for the accuracy or sufficiency thereof or for errors, omissions or misstatements, negligent or otherwise, relating thereto. In particular, but without limitation, no representation or warranty, express or implied, is or will be given as to the achievement or reasonableness of, and no reliance may be placed for any purpose on the accuracy or completeness of, any estimates, targets, projections or forecasts and nothing in these materials should be relied upon as a promise or representation as to the future.

The information and opinions contained in this document are provided as at the date hereof and are subject to change without notice. The recipient will be solely responsible for conducting its own assessment of the information set out in the Presentation. Neither the Company nor any of its affiliates, advisors or representatives shall be obliged to furnish or to update any information or to notify or to correct any inaccuracies in any information. Each of the Company or any such persons' directors, officers, employees or affiliates or any other person disclaim all and any responsibility and liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this Presentation or its contents or otherwise in connection with this Presentation.

Certain information contained in this Presentation may contain forward-looking statements which involve risks and uncertainties and are subject to change. All statements that address expectations or projections about the future, including statements about operating performance, market position, industry trends, general economic conditions, expected expenditures and financial results, are forward-looking statements. In some cases, these forward-looking statements can be identified by the use of words such as "believe", "anticipate", "estimate", "target", "potential", "expect", "intend", "predict", "project", "could", "should", "may", "will", "plan", "aim", "seek" and similar expressions. Any statements contained herein that are not statements of historical fact are forward-looking statements. The forecasts and forward-looking statements included in this document are necessarily based upon a number of assumptions and estimates that are inherently subject to significant business, operational, economic and competitive uncertainties and contingencies as well as assumptions with respect to future business decisions that are subject to change. By their nature, forward-looking statements involve known and unknown risks and uncertainties, because they relate to events, and depend on circumstances, that may or may not occur in the future. Furthermore, actual results may differ materially from those contained in any forward-looking statement due to a number of significant risks and future events which are outside of the Company's control and cannot be estimated in advance, such as the future economic environment and the actions of competitors and others involved on the market. These forward-looking statements speak only as at the date of this Presentation. The Company cautions investors that forward looking-statements are not guarantees of future performance and that its actual financial position, business strategy, plans and objectives of management for future operations may differ materially from those made in or suggested by the forward-looking statements contained in this Presentation. In addition, even if the Company's financial position, business strategy, plans and objectives of management for future operations are consistent with the forward-looking statements contained in this Presentation, those results or developments may not be indicative of results or developments in future periods. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Forward-looking statements should not be relied upon in making any investment decision. No representation or warranty is made as to the achievement or reasonableness of and no reliance should be placed on such forward-looking statements.

This Presentation is not for release or distribution or publication in whole or in part, directly or indirectly, in or into the United States, Australia, Canada or Japan or in any jurisdiction in which such a release or distribution is unlawful, and nothing contained herein shall form the basis of or be relied on in connection with any contract or commitment whatsoever. This Presentation is not a prospectus and does not contain or constitute an offer for sale or the solicitation of an offer to purchase securities in the United States, Canada, Australia, Japan or any other jurisdiction. These materials are not an offer for sale of securities.

This Presentation does not constitute a prospectus for the purposes of Directive 2003/71/EC (such Directive, together with any amendments thereto and any applicable implementing measures in the relevant home Member State under such Directive, the "Prospectus Directive").

This Presentation is only addressed and directed at (a) persons in member states of the European Economic Area ("Member States") who are "qualified investors" within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC as amended (including amendments by Directive 2010/73/EU to the extent implemented in the relevant Member State) ("Qualified Investors"); (b) within the United Kingdom, this Presentation is intended for distribution only to persons who (i) have professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or are high net worth companies, unincorporated associations or partnerships or trustees of high value trusts as described in Article 49(2) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) and investment personnel of any of the foregoing (each within the meaning of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005) and (ii) are "qualified investors" as defined in section 86 of the Financial Services and Markets Act 2000, as amended; (c) outside the United States to non-US Persons (as defined in Regulation S ("Regulation S") under the US Securities Act of 1933, as amended (the "Securities Act") in reliance upon Regulation S; and (d) other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "Relevant Persons"). This document must not be made available (i) in the United Kingdom, to persons who are not Relevant Persons, and (ii) in any Member State other than the United Kingdom, to persons who are not Qualified Investors. No person should act or rely on this document and persons distributing this document must satisfy themselves that it is lawful to do so.

By accepting or reading a copy of this Presentation or by attending any presentation in connection herewith, you acknowledge and agree to be bound by the foregoing terms, conditions, limitations and restrictions.

Feb 2022 I Management Presentation I 1

CONFIDENTIAL - Ikonisys Company Presentation February 2022. Not to be distributed, directly or indirectly, in the United States, Canada, Australia or Japan.

A unique value proposition

MISSION

CORE ABILITY

PRODUCT

• A diagnostic company founded with the vision to revolutionize laboratories' workflow through automation and data analysis
• Automated detection, analysis and interpretation of rare and extremely rare cells
• Ikoniscope20 digital fluorescence microscope system - A combination of proprietary instrument, software

applications and reagents covered by numerous international patents

Ikonisys' technology enables early,

accurate cancer detection

We offer a unique fully-automated solution for diagnostics laboratories

Feb 2022 I Management Presentation I 2

CONFIDENTIAL - Ikonisys Company Presentation February 2022. Not to be distributed, directly or indirectly, in the United States, Canada, Australia or Japan.

1. A UNIQUE VALUE PROPOSITION IN DIAGNOSTICS
2. MARKET & COMMERCIALIZATION
3. SUCCESSFUL BUSINESS MODEL AND GROWTH STRATEGY
4. HIGHLIGHTS & ACHIEVEMENTS SINCE THE IPO

A clear need for fully automated systems in cancer diagnostics

Cancer: a deadly burden for humankind

18m		44m
	2018
2018		9.6m
14m	32m	2018
8.2m
2012
2012
2012
New cancer	Living with and	Deaths from
incidence (p.a.)	after cancer	cancer (p.a.)

• Survival rates at 5 years, early stage vs late stage:

	Breast	Lung	Colorectal	Ovarian
Stage	>90%	>70%	>90%	>90%
I-II
Stage	~15%	~14%	~20%	~5%
III-IV

Shortage of pathologists is a bottleneck for diagnosis

-18%	● The decrease between 2007-2017 in the number of active
pathologists in the US
63%	● The percentage of active US pathologists aged 55 years or
more
44%	● The portion of active UK pathologists that already work
overtime
24%	● The percentage of UK pathology labs that have to outsource
service on a weekly basis because of shortage of pathologists
	Implication: pathologists will need digital, automated
	systems to deliver more outcomes in less time, with
	higher specificity / granularity of data

• Results of recent market survey:
• • Users of automated systems are aware of system advantages (e.g. efficiency, throughput, less handling risks)
  • 60% of automated users plan to purchase a new automated system within the next 2 to 3 years (add on)
  • Above 80% of users would want to buy a fully automated and integrated system

Source: International Agency for Research on Cancer (Globocan 2018), Cancer Research UK,

Personalized Medicine Coalition (2017), DLS Consulting

Feb 2022 I Management Presentation I 4

CONFIDENTIAL - Ikonisys Company Presentation February 2022. Not to be distributed, directly or indirectly, in the United States, Canada, Australia or Japan.